PMV Pharmaceuticals pmvpharma.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

PMV Pharma (NASDAQ: PMVP) develops first-in-class p53 and p53 pathway modulators for the treatment of cancer. p53 is the most commonly mutated gene in cancer, with over 50 percent of all human tumors containing a p53 mutant protein. The company combines a unique biological understanding with a pharmaceutical development focus.

PMV Pharma (NASDAQ: PMVP) develops first-in-class p53 and p53 pathway modulators for the treatment of cancer. p53 is the most commonly mutated gene in cancer, with over 50 percent of all human tumors containing a p53 mutant protein. The company combi...Show all

Company (IPO / Went public)

Phone: 609-642-6664

Fax:

8 Clarke Drive
Suite 3
Cranbury, 08512
New Jersey, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
PMV Pharmaceuticals $236M Sep 25, 2020

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related PMV Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 12 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods and compounds for restoring mutant p53 function Oct 18, 2018 May 05, 2020 Patent
Methods and compounds for restoring mutant p53 function Feb 17, 2017 Nov 27, 2018 Patent
Methods and compounds for restoring mutant p53 function Mar 16, 2020 Application